SCHEMBL206393

SCHEMBL206393

Fc1ccc2n[c]ccc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.47
KDM4E B2RXH2 3/20 0.38
KMT2A Q03164 3/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2A6 P11509 1/20 0.37
GFER P55789 2/20 0.36
AXL P30530 1/20 0.36
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
NFE2L2 Q16236 1/20 0.34
MAPT P10636 3/20 0.33
MEN1 O00255 2/20 0.33
ALDH1A1 P00352 2/20 0.33
ALPL P05186 1/20 0.33
ALPI P09923 1/20 0.33
ALPG P10696 1/20 0.33
LMNA P02545 1/20 0.33
PKM P14618 1/20 0.33
ALOX12 P18054 1/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL209493 0.83 KDM4E (0.38) BACE1KDM4EKMT2ACYP1A2CYP2A6
SCHEMBL5093567 0.77 PDGFRB (0.32) KDM4ECYP1A2ALDH1A1
SCHEMBL407633 0.75 CYP1A2 (0.55) BACE1KDM4EKMT2ACYP1A2CYP2A6
SCHEMBL208188 0.75 F7 (0.38) BACE1KDM4ECYP2A6PDE3BPDE3A
SCHEMBL208135 0.75 BACE1 (0.47) BACE1KDM4EKMT2ACYP1A2CYP2A6
SCHEMBL7630593 0.75 KDM4E (0.52) KDM4EKMT2AMAPTMEN1ALDH1A1
SCHEMBL1552052 0.75 ESR2 (0.44) KDM4EKMT2ACYP1A2PDE3BPDE3A
SCHEMBL407917 0.75 BACE1 (0.51) BACE1KDM4EPKM
SCHEMBL210465 0.72 MAPT (0.31) MAPT
SCHEMBL16289220 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 271 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111094233-B Compounds, compositions, and methods 戴纳立制药公司 2024-03-15 CN claimed
CN-110950842-B Quinoline derivatives having indoleamine-2, 3-dioxygenase inhibitory activity 深圳微芯生物科技股份有限公司 2023-06-20 CN claimed
CN-114105960-A Oxaadamantane derivatives capable of inhibiting activity of indoleamine 2, 3-dioxygenase 齐鲁制药有限公司 2022-03-01 CN claimed
US-20210379052-A1 QUINOLINE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITORY ACTIVITY SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) 2021-12-09 US claimed
EP-3858813-A1 QUINOLONE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITED ACTIVITY Shenzhen Chipscreen Biosciences Co., Ltd. (CN) 2021-08-04 EP claimed
CN-113045488-A Indoleamine 2, 3-dioxygenase inhibitors 齐鲁制药有限公司 2021-06-29 CN claimed
US-20210147435-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2021-05-20 US claimed
EP-3665156-A1 COMPOUNDS, COMPOSITIONS AND METHODS Denali Therapeutics Inc. (US) 2020-06-17 EP claimed
CN-108912070-B Synthetic method of epoxy compound and agricultural biological activity thereof 青岛农业大学 2020-06-02 CN claimed
CN-111094233-A Compounds, compositions and methods 戴纳立制药公司 2020-05-01 CN claimed
CN-1021823-C Substituted chroman compounds for treatment of asthma, arthritis and the like PFIZER (US) 1993-08-18 CN claimed
EP-0313295-B1 SUBSTITUTED TETRALINS, CHROMANS AND RELATED COMPOUNDS IN THE TREATMENT OF ASTHMA, ARTHRITIS AND RELATED DISEASES PFIZER INC. (US) 1993-07-28 EP claimed
CN-1064864-A The tetraline that replaces and the preparation method of allied compound PFIZER (US) 1992-09-30 CN claimed
CN-1063489-A Substituted benzotetrahydropyridines and related compounds PFIZER (US) 1992-08-12 CN claimed
US-5059609-A Lipoxygenase inhibitors; leukotriene receptor blockers; psoriasis; antiulcer agents and myocardial infarctions PFIZER INC. (US) 1991-10-22 US claimed
WO-1990012006-A1 SUBSTITUTED 1-[3-(HETEROARYLMETHOXY)PHENYL]ALKANOLS AND RELATED COMPOUNDS IN THE TREATMENT OF ASTHMA, ARTHRITIS AND RELATED DISEASES PFIZER INC. (US) 1990-10-18 WO claimed
EP-0391624-A1 Substituted 1-[3-heteroarylmethoxy)phenyl] alkanols and related compounds in the treatment of asthma, arthritis and related diseases PFIZER INC. (US) 1990-10-10 EP claimed
CN-1032659-A Substituted tetralins, chromans and like compounds for the treatment of asthma, arthritis and like diseases PFIZER (US) 1989-05-03 CN claimed
EP-0313295-A2 Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases PFIZER INC. (US) 1989-04-26 EP claimed
EP-0037471-B1 1-AROYL-2-PHENYLAMINO-2-IMIDAZOLINES, THEIR PREPARATION AND THEIR PHARMACEUTICAL COMPOSITIONS BASF Aktiengesellschaft (DE) 1984-05-30 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210379052-A1 QUINOLINE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITORY ACTIVITY IDO1, IDO2, INMT BACE1 3475/4885KDM4E 106/4885KMT2A 32/4885
US-20210147435-A1 COMPOUNDS, COMPOSITIONS AND METHODS EIF4EBP1, EIF4B, EIF4E BACE1 3801/4885KDM4E 2439/4885KMT2A 3980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.